Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9Head & Neck 2Gynecologic 2Breast 2Thoracic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 29Carcinoma, Renal Cell 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Melanoma 6Small Cell Lung Carcinoma 5Ovarian Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Merkel Cell 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Lung Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Uveal Melanoma 1Turcot syndrome 1Thymoma 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Microsatellite Instability 1Mesothelioma 1

Interventions

pembrolizumab 39Gemcitabine 30Nivolumab 15Cetuximab 13Carboplatin 13Cyclophosphamide 12Cisplatin 12Irinotecan 10Docetaxel 10130-nm albumin-bound paclitaxel 10Trastuzumab 8Magnetic Resonance Spectroscopy 8fludarabine 7aldesleukin 7Paclitaxel 7Drug Therapy 7Bevacizumab 7Taxes 6Specimen Handling 6Fluorouracil 6Capecitabine 6Albumin-Bound Paclitaxel 6sargramostim 5Pemetrexed 5Oxaliplatin 5Ipilimumab 5spartalizumab 4durvalumab 4Standard of Care 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × avelumab × Thoracic × Clear all
NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡